Geron Corp. Daily Stock Analysis

Daily Stock Analysis, GERN, Geron Corp, priceseries

Geron Corp. Daily Stock Analysis
Stock Information
Open
1.02
Close
1.03
High
1.06
Low
1.02
Previous Close
1.02
Daily Price Gain
0.01
YTD High
1.31
YTD High Date
Jan 4, 2022
YTD Low
0.99
YTD Low Date
Feb 4, 2022
YTD Price Change
-0.28
YTD Gain
-21.37%
52 Week High
2.23
52 Week High Date
Jun 18, 2021
52 Week Low
0.99
52 Week Low Date
Feb 4, 2022
52 Week Price Change
-0.74
52 Week Gain
-41.81%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
May 11. 2017
2.68
May 26. 2017
2.93
11 Trading Days
9.39%
Link
LONG
Jan 22. 2018
1.97
Feb 8. 2018
2.42
13 Trading Days
23.09%
Link
LONG
Feb 28. 2018
2.31
Mar 28. 2018
4.53
20 Trading Days
96.17%
Link
LONG
Apr 12. 2018
3.99
Apr 13. 2018
4.30
1 Trading Days
7.89%
Link
LONG
May 21. 2018
3.63
May 31. 2018
4.10
7 Trading Days
12.85%
Link
LONG
Jan 31. 2019
1.15
Feb 28. 2019
1.48
19 Trading Days
28.94%
Link
LONG
Mar 11. 2019
1.49
Mar 25. 2019
1.62
10 Trading Days
8.91%
Link
LONG
Apr 2. 2019
1.74
Apr 15. 2019
1.86
9 Trading Days
6.93%
Link
LONG
Jun 15. 2020
1.68
Jul 13. 2020
2.03
19 Trading Days
20.96%
Link
LONG
Oct 2. 2020
1.82
Oct 16. 2020
1.97
10 Trading Days
8.24%
Link
LONG
Jan 29. 2021
1.78
Feb 10. 2021
1.96
8 Trading Days
9.92%
Link
LONG
Aug 20. 2021
1.27
Sep 8. 2021
1.38
12 Trading Days
9.00%
Link
Company Information
Stock Symbol
GERN
Exchange
NasdaqGS
Company URL
http://www.geron.com
Company Phone
6504737700
CEO
John A. Scarlett
Headquarters
California
Business Address
149 COMMONWEALTH DRIVE, SUITE 2070, MENLO PARK, CA 94025
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000886744
About

Geron Corp. discovers and develops therapeutic products for cancer. It is a clinical stage biopharmaceutical company, which develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Geron was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park, CA.

Description

Geron Corporation operates as a biopharmaceutical company. The company supports the clinical stage development of a telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading